AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 ...

AstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, worth up to $6 billion. The deal covers DS-1062, Daiichi Sankyo’s proprietary ...

Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market in the UK, through a ground-breaking collaboration with AstraZeneca.

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...

STAMPEDE otherwise follows a line of randomized trials (e.g., MAST, TAXOMET, IMPROVE) that have failed to prove cancer ...

During a live event, Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and ...

Jazz Pharmaceuticals plc is a Buy with its robust portfolio, potential FDA approvals, and innovative oncology treatments.

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...

See the latest AstraZeneca PLC ADR stock price (AZN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients Apr. 21, 2025 at 8:05 a.m. ET on Benzinga.com ...

Review the current AstraZeneca PLC ADR (AZN:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if AZN is the best investment for you.